Abstract
Fatal and nonfatal cardiovascular events are the most important cause of graft loss in patients with a functioning graft following transplantation. The available data indicate that transplant patients have a high prevalence of hypertension, hyperlipidaemia and new onset diabetes mellitus after transplantation. The aetiology and pathogenesis of post-transplant hypertension, hyperlipidaemia and diabetes are multifactorial. In addition, disease of the native kidney and recurrence of renal disease can contribute to the development of cardiovascular disease in transplant recipients. Most transplant patients are at risk of clinically important drug-drug interactions involving immunosuppressive agents. Adverse reactions and drug-drug interactions should not be neglected when selecting an agent for treatment of cardiovascular risk factors in transplant recipients.
Original language | English (US) |
---|---|
Pages (from-to) | 29-44 |
Number of pages | 16 |
Journal | Expert Opinion on Drug Safety |
Volume | 4 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2005 |
Externally published | Yes |
Keywords
- Cardiovascular complications
- Diabetes
- Hyperlipidaemia
- Hypertension
- Immunosuppressive
- Renal transplant
ASJC Scopus subject areas
- Pharmacology (medical)